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 V. amygdalina possesses therapeutic values against plethora of health abnormalities. 
 V. amygdalina is an excellent source of vital phytochemicals and nutrients. 
 The leaves of V. amygdalina are consumed directly as vegetables in traditional soups. 
 The efficacy of V. amygdalina in improving health is linked to its bioactives and 
antioxidant contents. 
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Background: Vernonia amygdalina is traditionally used to treat a variety of diseases including 
diarrhoea, fungal and bacterial infections, inflammation, cancer, diabetes, and its squeezed 
juice can be applied on wounds.  
Objective: This study reviewed the phytochemistry, ethnopharmacological, and 
pharmacological potentials of Vernonia amygdalina. 
Methods: Literature search of relevant papers (1994-2021) were performed using 
ScienceDirect, Springer, Wiley and PubMed databases. For this review study, only publications 
written in English were utilized. 
Results: The bioactive compounds extracted from Vernonia amygdalina includes 6β,10β,14β 
trimethylheptadecan-15 α-olyl-15-O-β-D-glucopyranosyl-1,5 β olide, glucuronolactone, 11 α-
hydroxyurs-5,12-dien-28-oic acid-3 α,25-olide, 10-geranilanyl-O-β-D-xyloside, 1-heneicosenol 
O-β-D-glucopyranoside, apigenin, luteolin (3´,4´,5,7tetrahydroxyflavone), vernolide, 
hydroxyvernolide, 3'-deoxyvernodalol , vernodalol, diterpene (ingenol-3-angelate), 
vernomygdin, 4-methylumbelliferone, cephantharin, cryptolepine, isocryptolepine, 
neocryptolepine, courmarins, vernolepin, and vernoniosides. Various in vivo and in vitro studies 
revealed that V. amygdalina and its bioactive components possess pharmacological activities 
such as antioxidant, anti-inflammatory, anticancer, antimicrobial, hepatoprotective, 
antimicrobial, antidiarrheal, anti-diabetic, and neuroprotective activities. 
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Conclusion: This review demonstrated that V. amygdalina possess therapeutic effects against a 
wide variety of diseases. The efficacy of V. amygdalina in ameliorating diseases is attributed to 
its antioxidant activity and ability to improve the antioxidant system. Despite the vast 
pharmacological activities of V. amygdalina, more human clinical trials are needed to identify 
effective and safe doses for treatment of various diseases. 
 
Keywords: Vernonia amygdalina, pharmacological activities, phytochemicals, traditional uses. 
 
1. Introduction 
Recently, researchers have set out to uncover a new source of medicinal material that is 
generated naturally and has a less impact on human health, and the aquatic environment. Since 
organic herbal products are becoming increasingly popular as food supplements across the 
world, herbal plant-based approach is one of the choices accessible (Alara et al., 2019). Herbal 
medicinal practice makes use of phytochemicals found in plants; therefore, understanding and 
characterizing phytochemicals found in medicinal plants is critical for effective consumption 
and conservation (Alabi and Adeyemi, 2021). V. amygdalina is mostly cultivated and used in 
traditional medicinal practices in Africa and Asia's tropical areas (Oyeyemi et al., 2017). In the 
pharmacopeia, particularly in African origin, Vernonia amygdalina is one of the nutritionally and 
economically viable plants for its insect repellent and anti-tumor effects (Aregheore et al., 
1998; Oyeyemi et al., 2017).  
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Vernonia amygdalina is an angiosperm belonging to the order, Asterales (Toyang and 
Verpoorte, 2013). The plant belongs to the Asteraceae family, is grouped under the genus 
Vernonia, and species amygdalina. The genus is predominantly grown in the tropical regions 
and possesses several economic importance. The complete name of the plant is Vernonia 
amygdalina Del. (Toyang and Verpoorte, 2013). In Africa, V. amygdalina is the common name 
for this bitter-tasting plant (Abosi and Raseroka, 2003). The plant is predominantly cultivated in 
the tropical regions of Africa, especially in the West African (Tekou et al., 2018). In Igbo, Yoruba, 
and Hausa tribes of Nigeria, it is called as “Olugbu”, “Ewuro” and “Fetefete” respectively 
(Adesonoye et al., 2012). It is a soft woody shrub that grows perpetually to a height of 1 m to 6 
m. (IfedibaluChukwu et al., 2020). This shrub grows perpetually to a height of about 6 m and 
can withstand a broad range of weather conditions (Tekou et al., 2018). It is commonly called 
“bitter leaf” due to its characteristic bitter taste and this may be attributed to its anti-












Fig. 1. V. amydalina L. plant parts. A. Leaves of V. amydalina showing its phyllotaxy, B. Leaves 
with stalk-sourced from bushes located at Nwabuko Cresecent, Umuahia, Abia State, Nigeria. 
V. amygdalina leaves are 6 mm in diameter and 20 cm long (Habtamu and Melaku, 2018), it is 
dark green and is consumed in a wide variety of delicacies in African countries (Aregheore et al., 
1998). V. amygdalina leaves are high in nutrients such as vitamins, fibre, carbs, and minerals, 
making them an important part of the human diet (Oyeyemi et al., 2018).  Alara et al. reported 
some of the phytochemicals including alkaloids, tannins, saponins, flavonoids, polyphenols, 
alkaloids, anthraquinone, edotides, xanthones, coumarins and sesquiterpenes have been 
identified in the plant. These bioactive compounds have been extracted and analyzed using 
various techniques such as liquid chromatography with tandem mass spectrometry (LC-MS/MS) 
analysis (Hasibuan et al., 2020), microwave-assisted extraction (MAE) (Alara et al., 2019), 
soxhlet extraction (Tunasamy et al., 2019). Flavones extracted from flavonoids present in V. 
amygdalina include luteolin, luteolin 7-O-b-glucuronide, and luteolin7-O-b-glucoside (Alabi and 
Adeyemi, 2021).  
The pharmacological significance of V. amygdalina is due to the bioactive chemicals isolated 
from the plant leaves. Cold water extract of V. amygdalina has reportedly been used in the 
suppression of cancer (Yedjou et al., 2018), attenuation of dietary induced obesity (Atangwho 
et al., 2012), treatment of typhoid (Fadimu et al., 2014), inflammatory diseases (Asante et al., 
2019), malaria (Okpe et al., 2016), kidney diseases (Atangwho et al., 2012), and gastrointestinal 
disorders (Akah and Ekekwe, 1995). They also possess analgesic activity (Njan et al., 2008), 
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neuroprotective effects (Oladele et al., 2020), hepatoprotective effects (Iwolakun et al., 2006), 
antioxidant activity (Erukainure et al., 2018), and anti-allergic activity (Ngatu et al., 2012). 
Fadimu et al. (2014) contended that extracts of V. amygdalina could be employed in the 
treatment of sexually transmitted infections and urinary tract infections. Fevers, coughs, 
constipation, and hypertension have been successfully treated with tonics derived from 
extracts of V. amygdalina (Amira and Okubadejo, 2007).  Michael et al. (2010) also opined that 
V.  amygdalina extracts could be utilised in the treatment of eczema and maintenance of 
healthy blood glucose levels. Although there is limited information as regards to the toxicity of 
V.  amygdalina, Njan et al. reported on the toxicity of high dosage of extracts from the leaves. 
The aim of this review is to explore the pharmacological potentials of V. amygdalina and the 
extracted phytochemicals therein. This study will also provide relevant information on the 
beneficial effects of V. amygdalina as well as to incite further studies that may recommend the 
effectiveness and application of the extracts therein in the pharmacopeia and synthesis of new 
drugs. 
2. Methods 
All resources used for this review were collected solely from the internet databases Pubmed 
(https://pubmed.ncbi.nlm.nih.gov/), Springer (https://www.springer.com/gp), ScienceDirect 
(https://www.sciencedirect.com/) and Wiley (https://www.wiley.com/en-us) from 1994-2021 
(accessed 21 May 2021). The electronic online databases were opened. In the search tab, 
different phrase combinations and truncations of keywords were typed such as “V. amydalina 
and phytochem* OR “V. amydalina and ethnopharmac* OR “bitter leaf and pharmac* OR “V. 
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amydalina and phytochem* AND “bitter leaf and antioxidant” OR “V. amydalina and 
anticancer”, “bitter leaf and anti-diabetic” OR V. amydalina and hepatoprotective”, “V. 
amydalina and antimicrobial” OR “V. amydalina and antibacterial”. The title, abstract as well as 
the effect size of the searched articles were carefully read and reviewed whether they included 
relevant studies on the phytochemistry, ethnobotanical and pharmacological activities of V. 
amydalina. Only publications written in English were used in this review. 
3. Results and Discussion 
3.1. Ethnopharmacological uses of V. amygdalina L 
V. amygdalina has several medical, industrial, food, and traditional uses. The plant is used as a 
tonic in the treatment of fever, constipation, and many illnesses in traditional and herbal 
Nigerian medicine (Howard et al., 2016). These medicinal plant's herbal tonics are used in the 
treatment of sexually transmitted diseases. In general, the plant is cultivated to provide a 
significant source of edible vegetable. The plant is also used in the brewing industry as an 
alternative to hops in the production of beer. The Congolese maximizes V. amygdalina's 
medicinal potential by using it to treat cough and haemorrhoids (Ngatu et al., 2012). The leaves 
are frequently utilized in the treatment of malaria in Ethiopia. Several scientific studies have 
found that the herb has antioxidative, anti-inflammatory, and anticancer properties (Bihonegn 
et al., 2016).   
 3.2 Phytochemistry/bioactive compounds of Vernonia amygdalina L 
Alabi and Adeyemi uncovered several flavonoids (luteolin 7-O-b-glucuronide, luteolin 7-O-b-
glucoside) in V. amygdalina ethanolic preparations. All three flavones have strong antioxidant 
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properties, particularly luteolin (3´,4´,5,7 tetrahydroxyflavone). Other phytochemicals present 
include alkaloids, anthraquinone, steroid, phenol, phytate, oxalate, cyanogenic glycoside, 
tannins and saponins. Hasibuan et al.  used LC-MS/MS analysis to investigate the 
phytochemicals found in V. amygdalina. The findings revealed the presence of the following 
flavonoids: apigetrin, apigenin, luteolin, diosmetin, baicalin, rhoifolin, and scutellarin. Toyang 
and Verpoote examined the separated phytochemicals obtained from V. amygdalina extracts 
and showed that vernonioside A3, vernodalol, vernolepin, vernodalin, 11,13-dihydrovernodalin, 
and hydroxyvernolide are among the isolated bioactive chemicals and flavonoids. The reports 
of Adaramoye et al. showed that an increased content of flavonoids such as luteolin-7-O-
glucoside in mice treated against liver toxicity might be connected to a reduction in lipid 
peroxidation (LPO) levels in irradiated animals pretreated with V. amygdalina extracts.  
Using LC-MS analysis, Erukainure et al. identified the phytochemicals found in V. amygdalina. 
The study revealed the presence of nicotinic acid, cumidine, and 3-methyl-isoquinoline. V. 
amygdalina alkaloids were discovered and described by Omojokun et al.. The extract of 
alkaloids was quantified using GC-MS. 1-Hexanamine, dimethylamine, 1-fluorononane, 1,3-
cyclooctadiene, and hexadecanamide are examples of isolated alkaloid compounds. Iwolokun 
identified phytoconstituents with anti-plasmodial action from the extract and quinoline 
alkaloids such as cephantharin, cryptolepine, isocryptolepine, and neocryptolepine, as well as 
courmarins and terpenoids, are among these compounds.  
IfedibaluChukwu et al. isolated chemicals from V. amygdalina extracts ,including vernodalin, 
vernomygdin, vernoniosides A1, A2, A3, B1, vernoniosides A4, B2, B3, vernoniosides D and E, 
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vernodalol, epivern-odalol, phytol, and 4-methyl-vinyl butyrate, (z,z,z)-methyl ester-9,12,15-
octadecatrienoic acid. Several chemicals were isolated from methanolic stem-bark preparations 
using a chromatographic method including glucuronolactone (CMP3), 10-geranilanyl-O-β-D-
xyloside (CMP2), 11 α-hydroxyurs-5,12-dien-28-oic acid-3 α, 25-olide (CMP1), 1-heneicosenol 
O-β-D-glucopyranoside (CMP4) and 6β,10β,14β-trimethylheptadecan-15 α-olyl-15-O-β-D-
glucopyranosyl-1,5 β-olide (CMP5) (Vernoniaolide glucoside) (Table 1).  
Hasibuan et al. (2020) used LC-MS/MS analysis to investigate the phytochemicals contained in 
V. amygdalina. The findings revealed the presence of diterpene (ingenol-3-angelate) and 
phenolics (chlorogenic acid and 4-methoxycinnamic acid), as well as coumarines (7-
hydroxycoumarine, 4-methylumbelliferone, and 4-methylumbelliferyl glucuronide).  Alara et al. 
(2019) used Soxhlet method and MAE to identify bioactive components from ethanolic extracts 
of V. amygdalina. The gas chromatography-mass spectroscopy (GC-MS) analysis was used for 
further identification and confirmatory test was performed utilizing fourier transform infrared 
spectroscopy analysis. Among the isolated and described bioactives are 2-pentanol, pentanoic 
acid, 2-methyl-3-hexanol, and ethyl ester linoleic acid.   
3.3 Pharmacological activities of Vernonia amygdalina L 
3.3.1. Antidiarrhoeal activity 
Degu et al. investigated the antidiarrhoeal effects of V. amygdalina extracts against castor oil-
induced diarrhoea in mice. Cold maceration with 80% methanol was used to separate V. 
amygdalina extracts. Only at the highest tested dose (400 mg/kg.bw) V. amygdalina showed  a 
reduction in the beginning of diarrhoea, as well as a reduction in the frequency of stool and the 
         
11 
 
weight of faeces. V. amygdalina's inhibitory effects in this study highlight its antidiarrhoeal 
potential (Table 2). Shittu et al. evaluated the antidiarrheal activities of extracts of V. 
amygdalina against Vibrio cholerae induced diarrhoea mice. Single dose of 100 μL of V. cholera 
was inoculated into experimental rats. Administration of 250 mg/kg V. amygdalina 
demonstrated anti-inflammatory and anti-secretory activity in tissues of experimental mice. 
The inhibitory effects of V. amygdalina indicated in this study emphasize its antidiarrhoeal 
activity. 
3.3.2. Antioxidant activity 
The antioxidant activities of V. amygdalina have been reported by many researchers (Iwolakun 
et al., 2006; Tunasamy et al., 2019; IfedibaluChukwu et al., 2020). Iwolakun et al. investigated 
the anti-oxidative efficacy of V. amygdalina extracts against acetaminophen-induced in vivo 
toxicity in mice. Acetaminophen was injected at 300 mg/kg for 7 days. The pre-administration 
of the V. amygdalina extract at 50–100 mg/kg reduced oxidative stress. IfedibaluChukwu et al. 
used 2,2-diphenyl-1-picrylhydrazyl, nitric oxide, and hydrogen peroxide radical scavenging 
procedures in mice to investigate the anti-oxidative activities of isolates compounds from 
methanolic stem-bark extracts of V. amygdalina, they exhibited mild anti-oxidative action. 
Incubating brain tissues with V. amygdalina indicated a decrease 2-keto-glutaramic acid and 
cysteinyl-tyrosine metabolites in oxidative stress (Erukainure et al., 2018). Adesanoye et al. 
examined the chemoprotective properties of methanolic extracts of V. amygdalina (250 mg/kg 
and 500 mg/kg) against 2-acetylaminofluorene-induced hepatotoxicity in rats. by up-regulating 
the antioxidant enzymes. In another study, Ugbaja et al. reported the anti-oxidative activity of 
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flavonoid fractions of V. amygdalina in rats exposed to arsenic-induced oxidative stress. Erasto 
et al.  investigated the antioxidative activity of acetone, methanol and water extracts of V. 
amygdalina. The antioxidative activity of the extract was determined by detecting the reduction 
of the absorbance of DPPH and ABTS radicals at 519 and 734 nm, respectively. Results showed 
methanol extracts with highest antioxidative activity compared to the acetone and water 
extract. Methanolic extracts have antioxidative activity by scavenging 75.9%, 93.9%, 97.1%, and 
99.3% of the DPPH radicals from 0.01, 0.02, 0.05, and 0.1 mg/ml of extracts. Acetone extracts 
scavenged radicals between 63.3% and 91.7%. Results from this study elucidated the 
antioxidative activity of V. amygdalina. Lolodi and Eriyamremu also examined the antioxidative 
activity of methanolic extract of V. amygdalina. The antioxidative activity of the extract was 
determined by treating rats with 200 mg/kg dose of V. amygdalina after induction with normal 
diet containing 5% Cycas revoluta (cycads). Results revealed that administration of extract 
induced an increase in MDA levels and reduction in SOD levels compared to the control group. 
Omojokun et al. revealed that extract of the plant (0–30.51 g/mL) inhibited arginase while the 
alkaloid from the extract reduced Fe2+-induced lipid peroxidation (Table 2). 
3.3.3. Antimicrobial activity  
Studies have reported the antimicrobial activities of V. amygdalina (Ngatu et al., 2012; Oyugi et 
al., 2015; Dumas et al., 2020). Dumas et al. showed that extracts of V. amygdalina exhibited 
inhibitory activity on all tested bacteria including Staphylococcus aureus, Salmonella enterica 
and Klebsiella pneumoniae. Degbe et al. reported its inhibitory effect on Toxoplasma gondii, a 
protozoan parasite responsible for toxoplasmosis. Chloroform extract of V. amygdalina showed 
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strong activity against S. aureus with an inhibition zone of 21 mm. Isorhamnetin and acetone 
extracts were active against all bacterial pathogens tested (Habtamu and Melaku, 2018). Yusoff 
et al. evaluated the antifungal activity of the leaf extracts against Botrytis cinereal. Water 
extract of the plant at concentration range of 100–500 mg/mL, crude extracts of hexane, 
dichloromethane and methanol inhibited the fungus B. cinereal. However, the extract of V. 
amygdalina showed the most efficacies against the fungus. Extracts from dichloromethane at 
400 and 500 mg/mL showed mid severity of infection. Chukwuemeka et al. showed that the 
extract inhibited S. aureus, Bacillus subtilis, Salmonella typhi and Pseudomonas aeruginosa 
activities in mice. Ademola et al. examined the acetone extracts of V. amygdalina to determine 
its antiparasitic effects against the eggs and larvae of Haemonchus contortus. The extract 
inhibited hatching of eggs and larval development, also killing off H. contortus. Omoregie and 
Pal evaluated the antiplasmodial property of V. amygdalina against Plasmodium berghei 
induced in male Swiss rats. In vivo findings showed that the ethanolic extract of the plant 
suppressed the activity of P. berghei. Oral administration of 100 and 1000 mg/kg of the plant 
resulted in 23.7% and 82.3% inhibition of P. berghei respectively at day 4 (Table 2).  
3.3.4. Immunological effect  
Momoh et al. studied the effect of V. amygdalina on CD4+ cell count of HIV-infected patients on 
ART-regime for a year. Different doses of V. amygdalina and an immune booster, immunace, 
were administered in human clients. Results revealed an increase in CD4+ cell count of infected 
patients. Im et al. assessed the immune-modulatory activity of V. amygdalina by determining its 
effect on the haematological and lipid parameters of Rattus norvegicus. Different doses 
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including 50, 100, 200, 400 and 800 mg/kg of V. amygdalina were administered twice daily for 3 
weeks. Results from this analysis revealed a concentration dependent increase in CD4+ cell 
count, however, a reduction was observed at highest dose (800 mg/kg). The extract also 
induced an increase in white blood cells and lymphocytes. 
3.3.5. Anti-inflammatory activity 
Studies have shown the anti-inflammatory activities of V. amygdalina (Georgewill and 
Georgewill 2009; Nguyen et al., 2020; Liu et al., 2020). Nguyen et al. investigated the anti-
inflammatory effects of cynaroside and novel vernonioside V, isolated from ethanolic extracts 
of leaves of V. amygdalina. The findings from their research showed that vernonioside V at 
concentration of 30 mg/mL strongly inhibited the activities of tumour necrosis α (TNFα), 
interleukin-6 (IL-6), and interleukin-8 (IL-8) inflammatory cytokine production. These results 
indicated the anti-inflammatory potentials of V. amygdalina isolates. Liu et al. examined 
synthesized zinc oxide nanoparticles from V. amygdalina for anti-inflammatory activity in mice 
(Liu et al., 2020). V. amygdalina reduced the inflammatory response and pro-inflammatory 
cytokines levels in the mice. Asante et al. assessed extracts of young and old leaves of the 
extract to ascertain their ability to suppress inflammation, pain, and fever in carrageenan-
induced inflammation model in rats. Ethanol extracts of V. amygdalina were administered at 
50–200 mg/kg, alongside diclofenac (10 mg/kg). The findings from the study showed  a dose-
dependent increase in anti-inflammatory properties observed in both ethanol extracts of young 
and old leaves extract, similar to the standard drugs, diclofenac. Onasanwo et al.  reported that 
V. amygdalina possess anti-inflammatory effects through its ability in reducing inflammatory 
         
15 
 
leukocytes migration (Table 2). These reports justify the use of V. amygdalina extracts in the 
treatment of inflammation. 
 
3.3.6. Anticancer activity 
Hasibuan et al.  studied the anticancer effects of V. amygdalina leaves extracts on 4T1 breast 
cancer cells. V. amygdalina leaves induced apoptosis, increased cell accumulation in the G2/M 
phase of the cell cycle and inhibited intracellular signals such as PI3K and mTOR expression in 
4T1 breast cancer cells. Yedjou et al. investigated V. amygdalina extract's antiproliferative 
efficacy against human lung cancer (A-549) and human prostate cancer (PC-3) cells. From their 
findings, the extract suppresses the proliferation of both A-549 and PC-3 cells in a dose-
dependent manner. Yedjou et al. assessed the anticancer effects of the plant in MCF-7 cells. In 
the study, trypan blue exclusion test was utilized to distinguish between live and dead cells, and 
the propidium iodine (PI) assay with the cellometer vision was used for further analysis. Cell 
apoptosis was studied using flow cytometry. This study's findings revealed a reduction in cell 
viability in a concentration- and time-dependent manner. During the PI test, there was a steady 
rise in the number of necrotic cells (Table 2).  
Gresham et al. investigated V. amygdalina's anti-cancer efficacy in estrogen receptor-negative 
(ER-) breast carcinomas. Different doses of V. amygdalina (10, 100, and 1000 g/mL) were given 
to BT-549 cells, resulting in cell growth inhibition of around 14%, 22%, and 50%, respectively. 
Howard et al. investigated V. amygdalina's chemotherapeutic efficacy in TNBC cells and stem 
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cell-derived tumors. The results of this experiment revealed a substantial reduction in tumor 
volume in MDA-MB-468 cells when compared to HRAS cells. V. amygdalina increased cell 
apoptosis which inhibits tumour development, justifying its chemoprotective effect (Howard et 
al., 2016). Wong et al. revealed that the extract of V. amygdalina was shown to inhibit the 
proliferation of MCF-7 and MDA-MB-231 in a time- and dose-dependent manner through 3-
(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay. Growth suppression in 
MCF-7 cells was supplemented by inducing cell-type specific G1/S phase cell cycle arrest. In the 
study, the ability of V. amygdalina to suppress growth was characterized by a decrease in 
certain signalling factors including cyclin D1 and cyclin E levels, and an increased in p53 and p21 
levels. The extract induced cell apoptosis, as evidenced by an increase in Annexin V-positive 
cells and the sub-G1 population.  
Other studies that reported the anticancer activities include Hasibuan et al. investigated the 
anticancer efficacy of the extracts against 4T1 breast cancer cells. Bestari et al. examined its 
anti-cancer activity against WiDr colon cancer cell line. The researchers showed that the ethyl 
acetate extract of V. amygdalina possesses strong cytotoxic potential having the lowest IC50 
value (Bestari et al., 2017). Cameron et al. examined the anticancer activity of extracts of V. 
amygdalina against androgen independent prostate adenocarcinoma (PC-3 cells). [3H] 
thymidine incorporation assays were used to determine DNA synthesis. Values obtained from 
the results showed an inhibition of DNA synthesis 12%, 45% (P < 0.05), and 73% (P < 0.01) upon 
administration of extract at 0.01, 0.1 and 1 mg/ml doses.  Extract resulted in a time-dependent 
activation of MAPK activity. Result showed more anti-cancer activity compared to Taxol 
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protective activity. These results showed the anticancer activity of V. amygdalina. Opata and 
Izevbigie examined the anticancer activity of V. amygdalina in MCF-7 cells. 0–1000 µg/ml of V. 
amygdalina was inoculated into the cells. Extract at (0, 30, and 100 µg/ml) of V. amygdalina 
inhibited [3H] thymidine uptake. Extract (1 and 10 µg/ml) inhibited cell growth by 40% and 54% 
under serum-free conditions. Chukwuemeka et al. investigated the anticancer efficacy of the 
plant’s stem and leaves in mice, while Yedjou et al.  investigated the extracts for anti-cancer 
efficacy against human breast cancer in vitro (Table 2). Wang et al. investigated the cytotoxic 
activity of isolated steroidal saponins from V. amygdalina, namely vernoniamyosides A–D (1–4), 
vernoamyoside D (5), and vernonioside B2 (6). Vernoniamyoside A, vernoniamyoside B, and 
vernoniamyoside B2 were shown to be cytotoxic to BT-549 cell lines. Vernoniamyoside C, 
vernoniamyoside D, and vernoamyoside D exhibited varying degrees of cytotoxicity. The 
findings of this study provide a substantial basis for the use of V. amygdalina in anti-tumour 
research while also explaining its anti-cancer potential (Wang et al., 2018) (Table 2). Fachrunisa 
et al. investigated the cytotoxic activity, cell cycle inhibition, and apoptosis induction 
characteristics of V. amygdalina leaves' ethyl acetate extract on MCF-7 cancer cells. Treatment 
with ethyl acetate extract 1/2 IC50 and 1/5 IC50 resulted in cell cycle at 62.58% and 44.72%, 
respectively, compared to the cell control of 72.08%. These findings support V. amygdalina 
leaves' chemopreventive and anticancer properties.  
3.3.7. Anti-diabetic activity 
Studies have reported the anti-diabetic activities of V. amygdalina (Ong et al., 2010; Asante et 
al., 2016; Erukainure et al., 2018; IfedibaluChukwu et al., 2020). Asante et al. evaluated the anti-
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diabetic effects of young and old ethanolic leaf extracts of the resource plant against 
streptozotocin (STZ) induced diabetes in mice. IfedibaluChukwu et al. showed that isolated 
compounds from methanolic stem-bark extracts of V. amygdalina like 6β,10β,14β-
trimethylheptadecan-15 α-olyl-15-O-β-D-glucopyranosyl-1,5 β-olide had a significant reduction 
in the blood glucose in STZ-induced diabetic rats. Another study reported by Tekou et al. 
showed that oral administration of V. amygdalina for 4 weeks ameliorated type 2 diabetes in 
rats that were induced with STZ. Erukainure et al.  revealed that hot water infusion of the 
leaves of V. amygdalina had inhibitory activity against α-glucosidase, reduced intestinal glucose 
absorption, and enhanced muscle glucose uptake. Ong et al. showed that the protective actions 
of the extract on β-cells resulted in a rise in insulin levels and the favourable regulation of the 
antioxidant system may be responsible to its anti-diabetic activity. V. amygdalina increased 
skeletal muscle glucose uptake by boosting GLUT 4 translocation to the plasma membrane 
(Table 2).  
Michael et al. reported that the combination of V. amygdalina extract with metformin was 
potent against alloxan-induced diabetes in mice. Okon and Umoren investigated the 
antidiabetic activity of V. amygdalina against STZ (65 mg/kg) in type 1 diabetic rats.  52 mg/kg 
of V. amygdalina and 208 mg/kg of Ocimum gratissimum were administered orally for 28 days. 
Results revealed a hypoglycemic activity of V. amygdalina extracts. Owolabi et al. assessed the 
blood glucose lowering activity of V. amygdalina extracts against alloxan-induced diabetes in 
mice. Wu et al. assessed the antidiabetic effects of V. amygdalina against STZ-induced diabetes 
in mice. After 6 weeks of treatment with 50, 100, 150 mg/kg of V. amygdalina extracts revealed 
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a reduction in fasting blood glucose and also improved glucose and insulin resistance. Extract 
also induced an up-regulation in adenosine-5’monophosph kinase enzymes and inhibition of 
phosphoenolpyruvate carboxykinase and glucose-6-phosphatase. From the results obtained it 
can be concluded that extracts of V. amygdalina has antidiabetic activity. 
3.3.8. Hepatoprotective activity 
Iwolakun et al.  investigated the in vivo hepatoprotective properties of V. amygdalina extracts 
against acetaminophen-induced liver damage in mice. Pretreatment with the extract at doses 
ranging from 50 to 100 mg/kg alleviated the induced acetaminophen changes in liver function 
parameters by 51.9% to 84.9% (Iwolakun et al., 2006). Adasanoye et al.  studied the effects of 
methanolic extracts of V. amygdalina against carbon tetrachloride (CCl4) in male rats. Hepatic 
injury was induced by administering CCl4 orally at 1.2 g/kg 3 times a week for 3 weeks. 
Methanolic extracts of the plant were administered 5 times a week for 2 weeks prior CCl4 
treatment at 250 and 500 mg/kg doses of extract. Administration of the extract elevated the 
activities of antioxidant enzymes at 500 mg/kg concentration. Iwo et al. reported 
hepatoprotective effects of V. amygdalina extracts on intoxicated rats in combination with 
isoniazid and rifampicin (Table 2). Results from assessed serum albumin concentration and 
alanine amino transferase activity showed that the 100 mg/kg extract had hepatoprotective 
effect. Furthermore, the histological reports also revealed a minimal liver damage at 100 
mg/kg.  
Barnes et al. examined the protective activity of V. amygdalina extracts against heavy metal 
induced toxicity in liver and kidney. After 21 days of the extract administration, there were 
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reduction in elevated levels of AST, ALT, and GGT, urea and creatinine. Adaramoye et al. 
investigated the hepatoprotective effects of V. amygdalina and Hibiscus sabdariffa, as well as 
vitamin C, against gamma radiation (4 Gy)-induced liver damage in rats. The mice were given a 
vitamin C dose of 250 mg/kg.  Doses of 200, 400 and 800 mg/kg of V. amygdalina and Hisbiscus 
sabdariffa were given 4 weeks before and 5 weeks after radiation. The mice were sacrificed 
after 24 hours. At 24 hours, 800 mg/kg of V. amygdalina and vitamin C mixed extract resulted in 
an increase in blood alanine aminotransferase and aspartate aminotransferase activity. At 800 
mg/kg, V. amygdalina extract reduced blood conjugated bilirubin levels by 29%. The treatment 
resulted in a decrease in serum lipid peroxidation and an increase in hepatic superoxide 
dismutase levels. Vitamin C and V. amygdalina extracts at 400 and 800 mg/kg substantially 
reduced alkaline phosphatase and LPO levels. These findings also suggested hepatoprotective 
effect of the extract via anti-oxidative activities (Table 2).  
3.3.9. Neuroprotective properties 
Oladele et al. investigated the neuroprotective mechanism of V. amygdalina methanolic leaf 
extract in rats with nitrobenzene-induced neurological disease. The findings revealed a rise in 
dopamine, glutathione, and antioxidant enzyme levels, as well as a decrease in 
acetylcholinesterase activity, inflammatory and oxidative stress indicators. The findings of the 
study provide evidence for the therapeutic benefits of V. amygdalina methanol leaf extract on 
neurodegenerative diseases (Table 2).  
3.3.10. Antimalarial activity 
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Abosi and Raseroka tested the extracts of V. amygdalina's leaves and root bark for antimalarial 
efficacy against drug-resistant P. berghei in mice. A standard inoculum of 1 x 107 infected 
erythrocytes was utilized, and leaf and root-bark extracts at doses of 125, 250, or 500 mg/kg 
were given for 4 days. The results indicated that leaf and root bark extracts had a suppression 
level by 67% and 53.5%, respectively (Table 2). The study's findings demonstrate that 
administering an ethanol extract of V. amygdalina during early infection can reduce 
parasitaemia. Bihonegn et al.  tested the antimalarial activity of an 80% methanol extract and 
its solvent fractions of V. amygdalina leaves against P. berghei in mice. The extract produced a 
suppression of parasitaemia during a 4-day test in the following order 200mg/kg; 32.47% 
(±2.65), 400mg/kg; 35.40% (±3.14) and 600mg/kg; 37.67% (±2.50).   Okpe et al. discovered a 
rise in red blood cells and a recovery in packed cell volume in V. amygdalina treated groups in 
Plasmodium infected mice. Hepatic cells that had been injured by Plasmodium recovered after 
being given plant extracts. Challand and Willcox investigated the leaves of V. amygdalina for 
their efficacy in the treatment of unfinished malaria in patients aged 12 years and older. 
According to the findings of this study, 67% of patients had satisfactory clinical responses by 
day 14. Although 32% of these patients reported full parasite removal, 71% had recrudescence. 
Furthermore, no adverse effects were noted. Abey et al. investigated V. amygdalina's 
antimalarial efficacy against P. berghei in mice. Aqueous (Ver-H2O) and ethanolic (Ver-EtOH) 
leaf extracts were tested for their effectiveness against P. berghei sexual and asexual blood 
stages. The density of P. berghei was reduced by 50% due to Ver-H2O intake. P. berghei oocyst 
prevalence and density were decreased by 27% and 90%, respectively, when Ver-EtOH were 
administered. In vitro testing of 50 µg/mL Ver-EtOH revealed a high effectiveness in inhibiting 
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early sporogenic stage (ESS) formation (> 90%). Four fractions produced at this concentration 
from the ethylacetate phase of the methanol extract inhibited ESS (> 90%). These findings 
indicate that V. amygdalina includes its compounds have a strong antimalarial activity in 
Plasmodium stages.   
Yeshanew et al. examined the antimalarial activity of V. amygdalina in mice infected with 1×106 
P. berghei parasitemia. Administration of extract began after 3 hours of inoculation with 400, 
600, and 800 mg/kg of the extract administered orally for 4 consecutive days.  Parasitemia 
levels observed in highest treatment group was low 17.94±0.31 compared to the negative 
control group 46.53±1.23. Iwolakun showed combination antimalarial effect of V. amygdalina 
extracts and chloroquine (5 mg/kg) in the range (57.2-72.7%). The extract also reduced parasitic 
clearance times. In contrast to chloroquine monotherapy, combination of chloroquine and V. 
amygdalina resulted in a higher cure rate in P. berghei-infected mice (66.7 – 100 vs. 58.3%). 
These findings highlight V. amygdalina's antimalarial potential, demonstrating how extracts 
restore the effectiveness of chloroquine against P. berghei malaria in mice in a dose-dependent 
manner (Iwolakun, 2008). Masaba investigated the antimalarial effects of V. amygdalina on P. 
berghei obtained from a school kid and kept in liquid nitrogen in vitro. These experiments 
revealed that acetone-water and aqueous extracts of V. amygdalina have antimalarial activity, 
with the acetone-water extract being more effective (Table 2). These findings revealed V. 
amygdalina extracts' antimalarial activity.   
3.3.11. Analgesic activity 
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Njan et al. investigated the antinociceptive effect of V. amygdalina extracts (acetic acid-induced 
writhing, formalin test, and tail-flick test) (Table 2). The extract inhibited acetic acid-induced 
writhing and the formalin test, according to the results of this test. 
3.3.12. Cathartic effect 
Awe et al. investigated the cathartic effect of V. amygdalina using charcoal meal administered 
in mice. 50, 100 and 200 mg/kg of V. amygdalina were administered to mice in different 
groups. Results revealed increased motility of charcoal meal and increased number of feaces. 
These results emphasized the purgative activity of V. amygdalina.  
3.3.13. Anti-obesity activity 
Egedigwe et al. examined the anti-obesity activity of V. amygdalina in rats induced with high-fat 
diet. Rats were administered with 100 mg/kg.bw and 500 mg/kg.bw of aqueous extracts of V. 
amygdalina. Results showed a loss in weight of rats due to phytochemicals present in V. 
amygdalina, also reduction in insulin and leptin levels were observed in the extract treated 
groups. Atangwho et al. assessed the anti-obesity activity of V. amygdalina in diet induced 
obese rats. Extracts of V. amygdalina were administered at 5% and 15% supplemented with 
cafeteria-diet-fed to the treatment groups. Cafeteria-diet control group was administered 5.14 
mg/kg of Orlistat. Results showed a reduction in body weight gain by 12.78% and 38.51% in 
treatment groups. Total body fat was reduced by 28.04% and 30.02% by 5% and 15% of V. 
amygdalina, respectively. Intake of 15% V. amygdalina induced a down regulation of serum 
triacylgycerol, serum and brain total cholesterol (Table 2).  




From the review, Vernonia amygdalina displays outstanding pharmaceutics and nutritional 
uses, making it a great functional component utilized in the treatment of a variety of health 
abnormalities. This plant may be a superior substitute for traditional medication in the 
treatment of microbial infections, cancer, diarrhoea, anaemia, and inflammatory disorders 
since it is a good source of essential phytochemicals, nutrients, and bioactive isolates with a 
higher biological value. V. amygdalina extracts improve health by boosting antioxidant activity 
and systems. Despite V. amygdalina's extensive pharmacological activity, additional human 
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Table 1: Biological activities of compounds isolated from V. amygdalina 
Bioactive Compound Chemical Structure Biological 
Activity 
Reference 
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Table 2: Summary of the effects of V. amygdalina on different experimental models 
Doses Experimental models Observation Effects  References 
 125, 250 and 
500 mg/kg of 
V. 
amygdalina 




berghei in mice 
The extract produced 
53.5% and 67% 
suppression of 







200, 400 and 
600 mg/kg of 
V. 
amygdalina  
Inoculum of 0.2 mL 
P. berghei infected 
blood in mice 
 Produced 32.47, 35.40 
and 37.67% 
suppression of 










Inoculum of 1 × 10
6 
of P. berghei infected 
blood in mice 
The extract produced 
23.7% and 82.3% 
suppression of 






350 mg/kg of 
V. 
amygdalina 
Inoculum of 2.5 
×10
7
P. berghei in 
mice 
The extract resulted in 
the reduction of 
parasite load in mice 
Antimalarial 
activity 









berghei in mice 
The extract induced 
57.2- 72.7% 
suppression of 
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10, 50, 100 
and 200 
mg/kg of V. 
amygdalina 
 0.5% of Plasmodium 
falciparum and 1% 
haematocrit. 
The extract produced 
antimalarial activity 







400, 600, and 






 P. berghei 
parasitemia in mice  
The extracts had a 
suppressive effect of 
17.94% in parasitemia 
against 46.53% of 








200 and 400 
mg/kg of V. 
amygdalina 
100 mg/kg of  
 nitrobenzene in rats 
for 14 days 
Increased the levels of 
antioxidant enzymes, 
dopamine and reduced 






200, 100 and 
50 mg/kg 
doses of V. 
amygdalina  
300 mg/kg of 
acetaminophen for 7 
days in mice 
Acetaminophen- 
induced alterations 
occurring on the liver 
function parameters 










100 mg/kg of 2-
acetylaminofluorene 
for 7 days in mice 
Increased glutathione 
and antioxidant 






250, 500 and 
750 mg/kg 
doses of V. 
amygdalina 
1.2 g/kg of carbon 
tetrachloride 
administered 3 times 
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50 and 100 
mg/kg of V. 
amygdalina 
27 and 54 mg/kg of 
isoniazid (INH) and 
rifampicin 
respectively in rats 





Iwo et al. 
(2017) 
100, 200 and 
400 mg/kg of 
V. 
amygdalina  
5 mg/kg of cadmium 
for 5 days in rats  
Attenuated Cd-induced 
alterations in liver 
biomarkers (AST, 








200, 400 and 




400 rads from 
60
Co 
gamma chamber in a 
single dose. 
Induced a reduction in 
levels of serum liver 
enzymes and caused 
29% reduction of 








100, 200 and 




13 mg/kg Pb and 16 
mg/kg Cu in separate 
treatment groups for 
14 days. 
Extract ameliorated 
heavy metal induced 
toxicity by reduction of 
elevated ALT, AST, 















patients on ART 
regimen.  
 
Increased CD4 count 
by 4%. Combined dose 
of V. amygdalina and 
immunace increased 






50, 100, 200, Healthy Rattus Induced an increase in Immunological Im et al. 
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400 and 800 
mg/kg of V. 
amygdalina 
norvegicus fed 
extracts twice daily 
for 3 weeks. 
CD4
+
 cell counts, 
white blood cells and 
lymphocytes. 
activity (2016) 
10, 30 and 
300 mg/kg 
doses of V. 
amygdalina  
40 mg/kg of STZ for 






al. (2016)  
500 mg/kg of 
V. 
amygdalina 
40 mg/kg of STZ 
(single dose) in rats. 










Single dose of 55 














200, 400, 600 
mg/kg of V. 
amygdalina 
Single dose of 55 
mg/kg of STZ in rats 














Single dose of 65 








100 mg/kg of 
V. 
Single dose of 150 
mg/kg of alloxan 
The extracts in ratios 












monohydrate in rats decreased blood sugar 
levels.  








75 g of white bread in 
humans observed 
during a period of 
120 min 
The decoction induced 
a reduction in blood 




Ejike et al. 
(2013) 
 
50, 100, 150 




Single dose of 60 
mg/kg of STZ in 
mice after 12 hours of 
fasting. 





Wu et al. 
(2018) 
 




mg/kg of O. 
gratissimum 
Single dose of 65 
mg/kg of STZ 
Reduced the blood 






100 and 400 
mg/kg of V. 
amygdalina 
Single dose of 150 
mg/kg of alloxan in 
rats 






400 mg/kg of 
V. 
amygdalina 
Single dose of 65 
mg/kg of STZ in rats 




Ong et al. 
(2011) 
100 and 200 30 mg/0.3ml of Reduced post Lipid-lowering Adaramoye 






cholesterol five times 
weekly for 9 
consecutive weeks in 
rats 
mitochondrial fraction 
and plasma cholesterol. 
activity et al. 
(2008) 
2.5, 5.0, 7.5 
mg/kg doses 





administration of 1% 
acetic acid in mice 
observed for 30 mins 





Liu et al. 
(2020) 





100 μL of 2% 
carrageenan in rats. 
2 hours post treatment 
results showed 







doses of V. 
amygdalina  
2 ml of 2% 
carrageenan dissolved 
in saline solution 
inoculated in pouch 
cavity of rats 
The extract in 
combined dose with 
indomethacin (5 
mg/kg) produced a 
















 cells/mL of 
HL-60 promyelocytic 
leukemia cells after 
incubated for 24 
hours. 
The extracts induced 








125, 250, and 
500 μg /mL 
doses of V. 
Human prostate 
cancer (PC-3) cells 
treated with V. 
Antiproliferative 
activity with an IC50 
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amygdalina amygdalina extracts 
for 48 hours 
Inhibited cell growth, 
damaged DNA, and 







 and 4 x 10
4
 of 
MCF-7 cells  








125, 250, and 
500 μg/mL 
doses of V. 
amygdalina  
 (A-549) human lung 
cancer cells and (PC-
3) human prostate 
cancer cells treated 
for 48 hours. 




activity of the (A-549 















Induced early signs of 
apoptosis after 48 








10, 100, 1000 




carcinoma cell line 
(BT-549) observed 
for 24 hours  
14 %, 22 %, and 50 % 
growth inhibition was 
induced by 10, 100, 












of MCF-7 and 
MDA-MB-231 cells 
Inhibited cell growth 
by stimulation of G1/S 
phase cell cycle arrest, 
induced an increase in 
p53 and p21 levels. 
Anticancer 
activity 
Wong et al. 
(2013) 
0.01, 0.1 and 
1 mg/ml of V. 
Androgen 
independent prostate 
Induced an inhibition 












NF-B activation, and 
stimulated activation 
of MAPK.  
 (2013) 
 
150 μl/ml of 
15–240 
μg/ml of V. 
amygdalina 
75 μl of 0.3 mM of 
1,1-diphenyl-
2picrylhdrazyl in rats 
α-glucosidase and 
pancreatic lipase 
activity was inhibited 






100, 200, and 
400 mg/kg 
dose of V.  
amygdalina 
0.5 ml of castor oil in 
mice  
Reduced the frequency 
of wet defaecation.  
Antidiarrheal 
activity  
Degu et al. 
(2020) 





0.5 ml of castor oil in 
mice  
Reduced the frequency 
of wet and total stool 
as well as prolonged 





200, 300, and 
400 mg/kg of 
V. 
amygdalina 
150 mg/kg of aspirin 





and free and total 






200, 300 and 
400 mg/kg of 
V. 
amygdalina 
150 mg/kg of aspirin 
for 3 days in mice 
Lowered gastric ulcer 
score, gastric acid 
secretion, white blood 







Extracts of V. 
amygdalina 
supplemented 
5.14 mg/kg of 
Orlistat for 4 weeks 
in rats 
Reduced body weight 











at 5% at 
15%. 







inducing fat in Wistar 
rats and 5.14 mg/kg 
of Orlistat in 
treatment groups. 
Reduced body weight 






















for 6 hours. 
Suppression of t-BHP 












150 μL of 5 % of 
2,4,6-
trinitrochlorobenzene, 
subsequently 15 μL 
of 1 % 
trinitrochlorobenzene 
administered once in 
3 days in mice. 
Inhibited the 
development of atopic 
dermatitis and reduced 









Ngatu et al. 
(2012) 
 










These bacteria were 
sensitive to V. 
amygdalina at 25 
mg/ml, while E. coli 
and S. marcescens 













         
